Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 20/20 | 1.00 |
| ▸ | MMP3 | P08254 | 19/20 | 1.00 |
| ▸ | MMP2 | P08253 | 17/20 | 1.00 |
| ▸ | MMP1 | P03956 | 16/20 | 0.81 |
| ▸ | MMP7 | P09237 | 14/20 | 0.81 |
| ▸ | MMP9 | P14780 | 8/20 | 0.78 |
| ▸ | MMP8 | P22894 | 8/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256578 | 0.90 | MMP13 (0.81) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7249960 | 0.87 | MMP13 (1.00) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7256981 | 0.87 | MMP13 (0.79) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7245718 | 0.87 | MMP13 (1.00) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7239169 | 0.87 | MMP13 (1.00) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7456237 | 0.86 | MMP13 (0.78) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7251827 | 0.84 | MMP13 (0.77) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7250944 | 0.84 | MMP13 (1.00) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7078454 | 0.84 | MMP2 (0.73) | MMP13MMP3MMP2MMP1MMP7 | |
| SCHEMBL7252210 | 0.83 | MMP13 (0.81) | MMP13MMP3MMP2MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162778-A1 | Carbocyclic side chain containing metalloprotease inhibitors | THE PROCTER AND GAMBLE COMPANY | 2003-08-28 | — | — | US | disclosed |
| US-20030144292-A1 | Carbocyclic side chain containing, N-substituted metalloprotease inhibitors | PROCTER & GAMBLE COMPANY, THE | 2003-07-31 | — | — | US | disclosed |
| EP-1265887-A2 | CARBOCYCLIC SIDE CHAIN CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001070682-A2 | CARBOCYCLIC SIDE CHAIN CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162778-A1 | Carbocyclic side chain containing metalloprotease inhibitors | MMP2, CMA1, SERPINB1 | MMP13 24/4885MMP3 6/4885MMP2 1/4885 |
| US-20030144292-A1 | Carbocyclic side chain containing, N-substituted metalloprotease inhibitors | MMP2, MMP3, CMA1 | MMP13 20/4885MMP3 2/4885MMP2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.